NASDAQ:APVO Aptevo Therapeutics (APVO) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free APVO Stock Alerts $0.89 -0.05 (-5.32%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$0.88▼$0.9650-Day Range$0.68▼$6.6052-Week Range$0.67▼$80.96Volume188,546 shsAverage Volume2.07 million shsMarket Capitalization$382,700.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Aptevo Therapeutics alerts: Email Address Aptevo Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish16.76% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.20Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($8.85) to ($5.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.54 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Aptevo Therapeutics.Read more about Aptevo Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted16.76% of the float of Aptevo Therapeutics has been sold short.Short Interest Ratio / Days to CoverAptevo Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aptevo Therapeutics has recently increased by 84.20%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAptevo Therapeutics does not currently pay a dividend.Dividend GrowthAptevo Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APVO. Previous Next 4.0 News and Social Media Coverage News SentimentAptevo Therapeutics has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Aptevo Therapeutics this week, compared to 0 articles on an average week.Search Interest7 people have searched for APVO on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat Follows4 people have added Aptevo Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aptevo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.31% of the stock of Aptevo Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 8.06% of the stock of Aptevo Therapeutics is held by institutions.Read more about Aptevo Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Aptevo Therapeutics are expected to grow in the coming year, from ($8.85) to ($5.65) per share.Price to Book Value per Share RatioAptevo Therapeutics has a P/B Ratio of 0.06. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aptevo Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Aptevo Therapeutics Stock (NASDAQ:APVO)Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Read More APVO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APVO Stock News HeadlinesMay 8, 2024 | investorplace.comAPVO Stock Earnings: Aptevo Therapeutics Beats EPS for Q1 2024May 3, 2024 | americanbankingnews.comAptevo Therapeutics (NASDAQ:APVO) Stock Crosses Below 50-Day Moving Average of $3.62May 11, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.May 2, 2024 | msn.comWhy Aspen Aerogels Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving PremarketApril 11, 2024 | msn.comWhy Aptevo Therapeutics Stock Is CrateringApril 11, 2024 | investorplace.comWhy Is Aptevo Therapeutics (APVO) Stock Down 56% Today?March 7, 2024 | marketwatch.comAptevo Therapeutics Up 20% on Positive Interim Data for Tumor DrugMarch 7, 2024 | finance.yahoo.comAlligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4May 11, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 6, 2024 | ca.finance.yahoo.comAptevo Therapeutics Inc (AP8N.BE)March 6, 2024 | investing.comAptevo Therapeutics enacts reverse stock split to meet Nasdaq requirementsMarch 5, 2024 | investorplace.comAPVO Stock Earnings: Aptevo Therapeutics Beats EPS for Q4 2023March 5, 2024 | finance.yahoo.comAptevo Therapeutics Inc (AP8N.DU)March 4, 2024 | msn.comAptevo Therapeutics down 13%, will effect 1-for-44 reverse stock splitMarch 1, 2024 | uk.finance.yahoo.comPD-1 and PD-L1 Inhibitors Competitive Landscape Report 2024: Clinical Assessment of Over 200 Drugs Being Developed by More than 180 CompaniesFebruary 9, 2024 | investing.comAptevo Therapeutics Inc (APVO)February 7, 2024 | msn.comAptevo Therapeutics Stockholders Approve Reverse SplitJanuary 24, 2024 | finance.yahoo.comAptevo Therapeutics Inc. (APVO)November 22, 2023 | msn.comAptevo Therapeutics files to sell up to 32.03M shares of common stock for holdersNovember 14, 2023 | msn.comAptevo Therapeutics GAAP EPS of -$0.50November 14, 2023 | finance.yahoo.comAptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business UpdateNovember 1, 2023 | finanznachrichten.deAptevo Therapeutics: Aptevo to Present at Bio-Europe ConferenceNovember 1, 2023 | finance.yahoo.comAptevo to Present at Bio-Europe ConferenceOctober 21, 2023 | thestreet.comWith New Cash Aptevo Goes It Alone on Prostate Drug, Shares Up - Biotech MoversSeptember 26, 2023 | money.usnews.comAptevo Therapeutics IncAugust 10, 2023 | finance.yahoo.comAptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business UpdateAugust 4, 2023 | finance.yahoo.comAptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public OfferingSee More Headlines Receive APVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today5/11/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:APVO CUSIPN/A CIK1671584 Webwww.aptevotherapeutics.com Phone(206) 838-0500Fax206-838-0503Employees40Year Founded2016Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-112.27% Return on Assets-64.39% Debt Debt-to-Equity RatioN/A Current Ratio2.64 Quick Ratio2.64 Sales & Book Value Annual Sales$3.11 million Price / Sales0.12 Cash FlowN/A Price / Cash FlowN/A Book Value$28.58 per share Price / Book0.03Miscellaneous Outstanding Shares430,000Free Float427,000Market Cap$382,700.00 OptionableNot Optionable Beta5.13 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Marvin L. White (Age 62)President, CEO & Director Comp: $841.39kMr. Jeffrey G. Lamothe CA (Age 58)Executive VP & COO Comp: $722.51kMs. SoYoung Kwon J.D. (Age 55)LL.M., Senior VP, General Counsel, Business Development & Corporate Affairs Comp: $639.37kMs. Daphne L. Taylor (Age 58)Senior VP & CFO Dr. Dirk Huebner M.D. (Age 60)Chief Medical Officer Key CompetitorsAditxtNASDAQ:ADTXChina SXT PharmaceuticalsNASDAQ:SXTCOtonomyNASDAQ:OTICComera Life SciencesNASDAQ:CMRAHistogenNASDAQ:HSTOView All Competitors APVO Stock Analysis - Frequently Asked Questions Should I buy or sell Aptevo Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APVO shares. View APVO analyst ratings or view top-rated stocks. How have APVO shares performed in 2024? Aptevo Therapeutics' stock was trading at $7.9640 at the beginning of 2024. Since then, APVO stock has decreased by 88.8% and is now trading at $0.89. View the best growth stocks for 2024 here. When is Aptevo Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our APVO earnings forecast. How were Aptevo Therapeutics' earnings last quarter? Aptevo Therapeutics Inc. (NASDAQ:APVO) issued its quarterly earnings data on Tuesday, November, 14th. The biotechnology company reported ($22.00) EPS for the quarter, topping analysts' consensus estimates of ($28.16) by $6.16. When did Aptevo Therapeutics' stock split? Shares of Aptevo Therapeutics reverse split on Wednesday, March 6th 2024. The 1-44 reverse split was announced on Wednesday, March 6th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, March 6th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of Aptevo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO). Who are Aptevo Therapeutics' major shareholders? Aptevo Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Aptevo Therapeutics? Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:APVO) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmithForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchCharles Payne Demystifies OptionsUnstoppable ProsperityForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
